Determining patient prevalence with rare and ultra-rare diseases has long been a challenge for industry, investors and payers. Accurate prevalence data, along with the ability to locate patients that could benefit from a breakthrough ATMP, will enable companies to present their value story from the start of the R&D journey.

Come and see us at the 4th Annual Gene Therapy for Rare Disorderson the 22nd to 25th February, 2021.